Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

Core Insights - Corbus Pharmaceuticals Holdings, Inc. has made significant advancements in its oncology and obesity pipeline, with promising data from its CRB-701 program and the upcoming first human dosing of CRB-913 [2][5] Corporate and Program Updates - CRB-701 is a next-generation antibody drug conjugate targeting Nectin-4, showing a promising safety profile and efficacy in advanced tumors [3][5] - CRB-913 is a highly peripherally restricted CB1 receptor inverse agonist designed for obesity treatment, demonstrating a brain to plasma ratio fifty times lower than rimonabant [4][5] - The FDA granted Fast Track designation to CRB-701 for treating metastatic cervical cancer, with ongoing studies in the U.S. and Europe [6][5] Financial Results - For Q4 2024, the company reported a net loss of approximately $9.5 million, compared to a net loss of$8.0 million in Q4 2023 [8] - The total operating expenses for Q4 2024 increased to approximately $12.6 million, primarily due to product development and stock-based compensation costs [9] - As of December 31, 2024, the company had$149.1 million in cash and investments, expected to fund operations through Q3 2027 [9]